Lyell Immunopharma, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

LYEL$16.75+8.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue	$15	$34	$30	$50
Operating expenses:
Research and development	28,172	39,500	106,476	122,935
General and administrative	10,687	11,769	34,519	37,519
Other operating income, net	(1,591)	(730)	(648)	(2,796)
Impairment of long-lived assets	—	—	1,443	—
Total operating expenses	37,268	50,539	141,790	157,658
Loss from operations	(37,253)	(50,505)	(141,760)	(157,608)
Interest income, net	3,266	5,965	10,404	19,148
Other (expense) income, net	(4,859)	(43)	(2,369)	402
Impairment of other investments	—	—	—	(13,001)
Total other (loss) income, net	(1,593)	5,922	8,035	6,549
Net loss	(38,846)	(44,583)	(133,725)	(151,059)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	144	1,157	(90)	854
Comprehensive loss	$(38,702)	$(43,426)	$(133,815)	$(150,205)
Net loss per common share, basic and diluted1	$(2.13)	$(3.48)	$(8.38)	$(11.83)
Weighted-average shares used to compute net loss per common share, basic and diluted1	18,268	12,815	15,952	12,766

Amounts previously reported have been retroactively adjusted to reflect the 1-for-20 reverse stock split effected on May 30, 2025. See Note 2.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.